Giorgio Gandaglia1, Praful Ravi2, Firas Abdollah1, Abd-El-Rahman M Abd-El-Barr3, Andreas Becker4, Ioana Popa5, Alberto Briganti1, Pierre I Karakiewicz5, Quoc-Dien Trinh6, Michael A Jewett7, Maxine Sun5. 1. Department of Urology, Vita Salute San Raffaele University, Milan, Italy; 2. West Middlesex University Hospital, London, United Kingdom; 3. Vattikuti Urology Institute, Henry Ford Health Systems, Detroit, MI; 4. Department of Urology, Prostate Cancer Center, University of Hamburg-Eppendorf, Hamburg, Germany; 5. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC; 6. Department of Surgery, Division of Urology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 7. Department of Surgical Oncology, Division of Urology, University Health Network, Toronto, ON.
Abstract
INTRODUCTION: This is a timely update of incidence and mortality for renal cell carcinoma (RCC) in the United States. METHODS: Relying on the Surveillance, Epidemiology, and End Results (SEER) database, we computed age-adjusted incidence, mortality rates and 5-year cancer-specific survival (CSS) for patients with histologically confirmed kidney cancer between 1975 and 2009. Long-term (1975-2009) and short-term (2000-2009) trends were examined by joinpoint analysis, and quantified using the annual percent change (APC). The reported findings were stratified according to disease stage. RESULTS: Age-adjusted incidence rates of RCC increased by +2.76%/year between 1975 and 2009 (from 6.5 to 17.1/100 000 person-years, p < 0.001), and by +2.85%/year between 2000 and 2009 (p < 0.001). For the same time points, the corresponding APC for the incidence of localized stage were +4.55%/year (from 3.0 to 12.2/100 000 person years, p < 0.001), and +4.42%/year (p < 0.001), respectively. The incidence rates of regional stage increased by +0.88%/year between 1975 and 2009 (p < 0.001), but stabilized in recent years (2000-2009: +0.56%/year, p = 0.4). Incidence rates of distant stage remained unchanged in long- and short-term trends. Overall mortality rates increased by +1.72%/year between 1975 and 2009 (from 1.2 to 5.0/100 000 person-years, P<0.001), but stabilized between 1994 and 2004 (p = 0.1). Short-term mortality rates increased in a significant fashion by +3.14%/year only for localized stage (p < 0.001). INTERPRETATION: In contemporary years, there is a persisting upward trend in incidence and mortality of localized RCC.
INTRODUCTION: This is a timely update of incidence and mortality for renal cell carcinoma (RCC) in the United States. METHODS: Relying on the Surveillance, Epidemiology, and End Results (SEER) database, we computed age-adjusted incidence, mortality rates and 5-year cancer-specific survival (CSS) for patients with histologically confirmed kidney cancer between 1975 and 2009. Long-term (1975-2009) and short-term (2000-2009) trends were examined by joinpoint analysis, and quantified using the annual percent change (APC). The reported findings were stratified according to disease stage. RESULTS: Age-adjusted incidence rates of RCC increased by +2.76%/year between 1975 and 2009 (from 6.5 to 17.1/100 000 person-years, p < 0.001), and by +2.85%/year between 2000 and 2009 (p < 0.001). For the same time points, the corresponding APC for the incidence of localized stage were +4.55%/year (from 3.0 to 12.2/100 000 person years, p < 0.001), and +4.42%/year (p < 0.001), respectively. The incidence rates of regional stage increased by +0.88%/year between 1975 and 2009 (p < 0.001), but stabilized in recent years (2000-2009: +0.56%/year, p = 0.4). Incidence rates of distant stage remained unchanged in long- and short-term trends. Overall mortality rates increased by +1.72%/year between 1975 and 2009 (from 1.2 to 5.0/100 000 person-years, P<0.001), but stabilized between 1994 and 2004 (p = 0.1). Short-term mortality rates increased in a significant fashion by +3.14%/year only for localized stage (p < 0.001). INTERPRETATION: In contemporary years, there is a persisting upward trend in incidence and mortality of localized RCC.
Authors: John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck Journal: J Natl Cancer Inst Date: 2006-09-20 Impact factor: 13.506
Authors: Rebecca Smith-Bindman; Diana L Miglioretti; Eric Johnson; Choonsik Lee; Heather Spencer Feigelson; Michael Flynn; Robert T Greenlee; Randell L Kruger; Mark C Hornbrook; Douglas Roblin; Leif I Solberg; Nicholas Vanneman; Sheila Weinmann; Andrew E Williams Journal: JAMA Date: 2012-06-13 Impact factor: 56.272
Authors: Maxine Sun; Firas Abdollah; Marco Bianchi; Quoc-Dien Trinh; Claudio Jeldres; Rodolphe Thuret; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Ann Surg Oncol Date: 2012-02-10 Impact factor: 5.344
Authors: Steven M Monda; Jonathan R Weese; Barrett G Anderson; Joel M Vetter; Ramakrishna Venkatesh; Kefu Du; Gerald L Andriole; Robert S Figenshau Journal: Urology Date: 2018-02-05 Impact factor: 2.649
Authors: Katie S Murray; Emily C Zabor; Massimiliano Spaliviero; Paul Russo; Wassim M Bazzi; John E Musser; A Ari Hakimi; Melanie L Bernstein; Guido Dalbagni; Jonathan A Coleman; Helena Furberg Journal: World J Urol Date: 2016-04-22 Impact factor: 4.226
Authors: Oktay Halit Aktepe; Gürkan Güner; Deniz Can Güven; Taha Koray Şahin; Fadime Sinem Ardıç; Deniz Yüce; Şuayib Yalçın; Mustafa Erman Journal: Turk J Med Sci Date: 2021-04-30 Impact factor: 0.973